SOURCE: Indevus Pharmaceuticals, Inc.

May 02, 2006 17:07 ET

Indevus Pharmaceuticals to Announce Second Quarter Fiscal 2006 Financial Results on May 8, 2006

Company to Conduct Conference Call and Webcast

LEXINGTON, MA -- (MARKET WIRE) -- May 2, 2006 --Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) will announce its second quarter 2006 financial results in a press release to be issued before market open on May 8, 2006. The Company will host a conference call and webcast to discuss these results at 9:00 AM eastern time on May 8, 2006.

The live call may be accessed by dialing 800-261-3417 from the U.S. and Canada, and 617-614-3673 from international locations. The participant passcode is 56622520. A replay of the call will be available beginning at 11:00 AM on May 8, 2006 and lasting until 12:00 AM on June 8, 2006. To access the replay, please dial 888-286-8010 from the U.S. and Canada, and 617-801-6888 from international locations, using the passcode 47241607.

The press release and the live webcast will be accessible by visiting the Investors section of the Company's website, An archived version of the call will be accessible at the same web address for 30 days following the live call.

About Indevus

Indevus Pharmaceuticals is a biopharmaceutical company engaged in the acquisition, development and commercialization of products targeting certain medical specialty areas, including urology, gynecology and men's health. The Company currently markets SANCTURA® for overactive bladder and DELATESTRYL® for the treatment of male hypogonadism. The Company has multiple compounds in clinical development, including SANCTURA XR™, the once-daily formulation of SANCTURA, NEBIDO® for the treatment of male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually transmitted pathogens, IP 751 for interstitial cystitis, pagoclone for stuttering, and aminocandin for systemic fungal infections.

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA® and SANCTURA XR™; the early stage of products under development; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA, SANCTURA XR and NEBIDO®; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR; dependence on third parties for manufacturing and marketing; competition; need for additional funds and corporate partners, including for the development of our products; failure to acquire and develop additional product candidates; history of operating losses and expectation of future losses; product liability and insurance uncertainties; risks relating to the Redux-related litigation; limited patent and proprietary rights; dependence on market exclusivity; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; and other risks.

Contact Information

  • Contact:
    Michael W. Rogers
    Executive Vice President and CFO
    (781) 861-8444

    Brooke D. Wagner
    VP, Corp. Communications
    (781) 402-3410